Behavioural Intervention
Individualized Elimination Diet for Eosinophilic Esophagitis
This trial is testing a new dietary treatment for an unspecified condition. The treatment will be given to some participants randomly, and others will be given a sham (fake) treatment. The trial is small and is only meant to test whether the treatment is feasible.
Monoclonal Antibodies
Barzolvolimab for Eosinophilic Esophagitis
This trial is testing a medication called barzolvolimab. It aims to help adult patients with Eosinophilic Esophagitis, a condition affecting the esophagus. The study will check if barzolvolimab can reduce inflammation and improve symptoms.
Popular Filters
Trials With No Placebo
Proteinase Inhibitor
Alpha-proteinase Inhibitor for Eosinophilic Esophagitis
This trial is testing Zemaira, a medication that protects tissues from damage, in patients with Eosinophilic Esophagitis. These patients have chronic inflammation in their esophagus due to an overactive immune response. Zemaira works by blocking harmful enzymes to reduce inflammation and prevent further damage.
Household Detergents and Eosinophilic Esophagitis
This trial is studying whether detergents in products like toothpaste can make the esophagus lining leaky and cause allergic reactions. It focuses on people who might have allergic inflammation in their esophagus due to these detergents.
Monoclonal Antibodies
Dupilumab for Eosinophilic Esophagitis
This trial tests if a treatment can help people with EoE reintroduce foods that usually cause their symptoms. The treatment works by reducing inflammation in the body, potentially allowing these patients to eat foods like milk, egg, wheat, and soy without issues.
Monoclonal Antibodies
Cendakimab for Eosinophilic Esophagitis
This trial is testing how a medication called cendakimab interacts with other drugs in people who have a condition affecting the esophagus. The goal is to see if cendakimab changes how these other medications work in the body.
Frequently Asked Questions
Introduction to eoe
What are the top hospitals conducting eoe research?
When it comes to advancing the understanding and treatment of eosinophilic esophagitis (EOE), several top hospitals are leading the way in clinical trials. In Cincinnati, the Cincinnati Children's Hospital Medical Center takes center stage with four active EOE trials and a remarkable 21 completed trials dedicated to this condition. Since conducting their first trial in 2001, this hospital has been at the forefront of research into EOE, a chronic allergic inflammatory disease that affects the esophagus.
Meanwhile, in Philadelphia, two renowned institutions are making significant contributions as well. The University of Pennsylvania is currently involved in three active EOE trials while having an impressive history of 18 completed studies since their inaugural trial in 2011. At the Children's Hospital of Philadelphia, researchers are also conducting three ongoing clinical trials for EOE while having conducted twelve previous studies since initiating their first trial in 2007.
In Los Angeles, Gastrointestinal Biosciences enters the scene as a key player with three active EOE trials. Although they might have fewer completed studies compared to other institutions due to being relatively new on the scene (their first recorded trial was just recently conducted in 2021), their dedication signifies promising progress towards understanding and combating this complex condition.
Lastly but not least important is Nature Coast Clinical Research LLC based in Inverness which contributes significantly by actively participating over time through three concurrent eoe investigations building upon six successfully accomplished projects from starting its pioneering investigations back from year2015
These esteemed hospitals and research centers across different locations demonstrate a shared commitment to unraveling the mysteries behind EOE - an illness that often goes unrecognized or misdiagnosed but can lead to severe complications if left untreated. Through these collaborative efforts involving cutting-edge clinical trials and years-long research endeavors – we inch closer every day toward better treatments and improved quality of life for individuals living with eosinophilic esophagitis
Which are the best cities for eoe clinical trials?
When it comes to eoe clinical trials, several cities have emerged as key hubs for research and development. Philadelphia, Pennsylvania leads the pack with 15 active trials exploring treatments like CC-93538, Dupilumab, and Barzolvolimab (CDX-0159). Cincinnati, Ohio follows closely behind with 12 ongoing studies focused on similar interventions such as CC-93538 and Dupilumab. Lastly, Boston, Massachusetts boasts 11 active trials examining options like CC-93538 and Barzolvolimab (CDX-0159), while Salt Lake City, Utah and Iowa City, Iowa also contribute to the advancement of eoe treatment through their respective clinical trials. These cities offer individuals dealing with eosinophilic esophagitis access to cutting-edge research that may lead to improved care options in the future.
Which are the top treatments for eoe being explored in clinical trials?
Exploratory clinical trials are paving the way for promising treatments in the management of eosinophilic esophagitis (EoE). One standout contender is Dupilumab, currently being tested in three active trials. Since its initial listing in 2015, it has amassed a total of four EoE trials, demonstrating its potential as a therapeutic option. Another noteworthy treatment under investigation is CC-93538, with two ongoing clinical trials and a total of three EoE trials since its recent introduction in 2021. These innovative therapies hold great promise for improving outcomes and quality of life for individuals living with EoE.
What are the most recent clinical trials for eoe?
Exciting progress is being made in the field of eosinophilic esophagitis (EOE) with recent clinical trials shedding light on potential treatment options. One notable trial involves an active drug specifically developed for EOE, which has entered Phase 2 and offers promise for patients. Additionally, Barzolvolimab (CDX-0159), another Phase 2 trial medication, shows encouraging results in its potential to address EOE symptoms effectively. With ongoing studies like Part A: Phase 2 for EOE and EP-104IAR 4 mg showcasing promising outcomes in their respective phases, there is growing hope that improved therapeutic approaches will emerge to alleviate the burden faced by individuals with this condition.
What eoe clinical trials were recently completed?
Several noteworthy clinical trials for eosinophilic esophagitis (EoE) have recently concluded, highlighting progress in the search for effective treatments. In October 2021, Revolo Biotherapeutics completed a trial investigating IRL201104 as a potential therapy. Last September, Ellodi Pharmaceuticals wrapped up their study on APT-1011. Additionally, Allakos, Inc. had two trials reach completion: one testing AK002 in May 2021 and another in November 2018. Other completed trials include Arena Pharmaceuticals' Etrasimod in December 2020; lirentelimab by Allakos, Inc., also in December 2020; Mepolizumab 300 mg conducted by the University of North carolina at Chapel Hill in March 2019; Dupilumab sponsored by Regeneron Pharmaceuticals in September 2018; and Benralizumab led by Children's Hospital Medical Center Cincinnati in April 2018. These studies signify significant research efforts to advance our understanding and treatment options for EoE patients.